⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570237 | 0.94 | — | — | |
| SCHEMBL4343300 | 0.74 | — | — | |
| SCHEMBL3157381 | 0.74 | — | — | |
| SCHEMBL10013426 | 0.67 | — | — | |
| SCHEMBL3157378 | 0.67 | — | — | |
| SCHEMBL1472957 | 0.67 | — | — | |
| Ammonia Solution, Strong SCHEMBL19133455 | 0.67 | — | — | |
| SCHEMBL1471263 | 0.65 | — | — | |
| SCHEMBL20633205 | 0.62 | — | — | |
| Methylsulfanylmethane SCHEMBL5693391 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323340-A2 | E3 LIGASE BINDERS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023081505-A1 | ADJUVANT COMPOUNDS AND FORMULATIONS | ADJUVANCE TECHNOLOGIES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023049493-A1 | THIOPHENE-BASED LIPIDS | OREGON STATE UNIVERSITY (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-4153747-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
| EP-4121029-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | Amathus Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121072-A1 | CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | Amathus Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3941924-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| EP-3906063-A2 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | Intocell, Inc. (KR) | 2021-11-10 | — | — | EP | disclosed |
| EP-3891284-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2021-10-13 | — | — | EP | disclosed |
| WO-2012024604-A2 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011119549-A1 | TRIOXACARCINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-2321364-A2 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | Novomer, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2244694-A2 | THERAPEUTIC COMPOSITIONS COMPRISING AN AMINE-CONTAINING LIPID AND A PROTEIN | Shire Human Genetic Therapies, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010123545-A2 | ANGIOGENESIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010022388-A2 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009097332-A2 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-1185536-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000069862-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2000-11-23 | — | — | WO | disclosed |